MP70-05 PROSTATE MRI PIRADS VALIDATION FOR BIOPSIES 1 YEAR AFTER MRI FUSION TARGET PROSTATE PARTIAL GLAND ABLATION

Abstract

You have accessJournal of UrologyProstate Cancer: Localized: Ablative Therapy II (MP70)1 Apr 2020MP70-05 PROSTATE MRI PIRADS VALIDATION FOR BIOPSIES 1 YEAR AFTER MRI FUSION TARGET PROSTATE PARTIAL GLAND ABLATION Fernando Bianco*, Alberto Lopez, Alessandra Pluchino, Edward Gheiler, Ariel Kaufman, Jim Hu, Pedro Gonzalez, Gloria Egui-Benatuil, and Christopher Woodhouse Fernando Bianco*Fernando Bianco* More articles by this author , Alberto LopezAlberto Lopez More articles by this author , Alessandra PluchinoAlessandra Pluchino More articles by this author , Edward GheilerEdward Gheiler More articles by this author , Ariel KaufmanAriel Kaufman More articles by this author , Jim HuJim Hu More articles by this author , Pedro GonzalezPedro Gonzalez More articles by this author , Gloria Egui-BenatuilGloria Egui-Benatuil More articles by this author , and Christopher WoodhouseChristopher Woodhouse More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000950.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Fusion imaging - MRI/US - of the prostate represents an emerging technology tailored to precision cancer diagnosis and plausible treatment. Herein, we report on the impact of piRADS scale from MRIs performed after 1 year of MR/US Fusion Target (SmartTx) partial prostate gland cryoablation. We aimed to assess validity of pI-Rads system correlating with 1 year - post treatment MR/US fusion biopsies. METHODS: NCT02381990 clinicaltrials.gov was designed and aims to consistently evaluate treatment outcomes after MR fusion target partial prostate gland cryoablation. A multi-parametric prostate MRI was indicated 1 year after SmartTx. T2, DWI, ADC and DCE images were evaluated and scored according to the piRADS-2 system. MRI readings for this study was performed by two qualified radiologists. Subsequently, the protocol called for a Transperineal MR/US fusion biopsy in the office setting. 14-16 biopsy samples were taken according to the plan designed using MRI target findings, tissue from ablated areas and at random. We evaluated the correlation between the piRADS scores and biopsy pathology. Parametric and non-parametric statistics were performed. Significance level was determined by a p<0.05 RESULTS: A total of 498 patients underwent SmartTx between 2013-2019, of these 204 had procedure within a year and were not eligible for 1yrMRI. Of the reminder 294 patients, 230 underwent prostate biopsy, where 201 (87%) were Transperineal MR/US fusion biopsies. Their median (Interquartile) pre biopsy characteristics were: Age 72 (67,77); PSA 1.9 ng/ml (1.0,3.4); MRProstate Volume 36 cc (27,52); PSADensity 4% (3,9). Most patients had non palpable tumors (94%), On the biopsy prior to treatment 95(47%), 54(27%), 39(19%) and 13(7%) were 3+3,3+4,4+3 and 8-10, respectively. Overall 78 (39%) of patients had a positive biopsy. In total, 19,51,78,30 and 23 had piRADS of 1,2,3,4 and 5, respectively. The piRADS system correlated and predicted presence of cancer (P=0.000)-seeTable. No other risk factor listed nor cryoablation system, ultrasound system, fusion software predicted risk independently CONCLUSIONS: For men treated with partial gland cryoablation, our novel results show great discrimination and correlation for piRADS 1-2 signaling absence of cancer in 90% of these patients. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1056-e1057 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Fernando Bianco* More articles by this author Alberto Lopez More articles by this author Alessandra Pluchino More articles by this author Edward Gheiler More articles by this author Ariel Kaufman More articles by this author Jim Hu More articles by this author Pedro Gonzalez More articles by this author Gloria Egui-Benatuil More articles by this author Christopher Woodhouse More articles by this author Expand All Advertisement PDF downloadLoading ...